Advanced search
Publication Cover
International Journal of Hyperthermia Volume 38, 2021 - Issue 1
Submit an article Journal homepage
1,922
Views
9
CrossRef citations to date
0
Altmetric
Articles

Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Laure Doisya Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7783-0211
ORCID Icon,
Arnaud Cimierb Department of Urology, Jean Monnet University, Nord Academic Hospital, Saint-Etienne, France
,
Aurélien Adypagavanec Department of Urology, Kremlin-Bicêtre Academic Hospital, Bicêtre, France
,
Jochen Walza Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
,
Thibault Marquettea Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
,
Thomas Maubona Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
,
Stanislas Rybikowskia Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
,
Sami Fakhfakha Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
,
Kevin Loverdea Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
,
Nicolas Mottetb Department of Urology, Jean Monnet University, Nord Academic Hospital, Saint-Etienne, France
,
Jacques Iranic Department of Urology, Kremlin-Bicêtre Academic Hospital, Bicêtre, France
,
Eric Lechevallierd Department of Urology and Kidney Transplantation, Aix-Marseille University, APHM, Conception Academic Hospital, Marseille, France
,
Dominique Rossie Department of Urology, Aix-Marseille University, APHM, Nord Academic Hospital, Marseille, France
,
Gwenaelle Gravisf Department of Medical Oncology, Institut Paoli Calmettes Cancer Center, Marseille, France
&
Géraldine Pignota Department of Surgical Oncology 2, Institut Paoli Calmettes Cancer Center, Marseille, France
 show all
Pages 1633-1638 | Received 22 Mar 2021, Accepted 28 Oct 2021, Published online: 14 Nov 2021

References

  • Wong MCS, Fung FDH, Leung C, et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8(1):1129.
  • Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49(5):790–797.
  • Babjuk M, Burger M, Compérat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ). Eur Urol. 2019;76(5):639–657.
  • Arends TJH, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non–muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052.
  • Sousa A, Piñeiro I, Rodríguez S, et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):374–380.
  • de Jong JJ, Hendricksen K, Rosier M, et al. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer. 2018;4(4):395–401.
  • Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for Non-Muscle-Invasive Bladder Cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935–1944.
  • Irani J. Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC): prospects for thermochemotherapy. Prog En Urol. 2016;26(14):860–864.
  • Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2018;73(6):925–933.
  • Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer: intravesical BCG plus TUR vs TUR alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209–216.
  • van der Heijden AG, Verhaegh G, Jansen CFJ, et al. 2005; Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 173(4):1375–1380.
  • Gofrit ON, Shapiro A, Pode D, et al. 2004; Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 63(3):466–471.
  • Marquette T, Walz J, Rybikowski S, et al. 2020 ; [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG unresponsive non-muscle invasive bladder cancer patients]. Prog Urol. 30(1):35–40.
  • Balar AV, Kulkarni GS, Uchio EM, et al. 2019; Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). J Clin Oncol. 37(7_suppl):350–350..
  • Kamat AM, Lerner SP, O’Donnell M, et al. 2020; Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol. 2020:32201133.
  • Duplisea JJ, Mokkapati S, Plote D, et al. 2019; The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 37(10):2041–2049.
  • Kleinmann N, Matin SF, Pierorazio PM, et al. 2020; Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. S1470-2045(20):30147–30149.
  • Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52(4):1123–1129.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.